Colorectal Adenocarcinoma Metastatic in the LiverPhase 2HAIP-6192NCT07764497
Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis
A Phase 2 study testing Floxuridine (FUDR) in people with Colorectal Adenocarcinoma Metastatic in the Liver and Liver Metastasis Colon Cancer, run by Sunnybrook Health Sciences Centre at 1 site in Canada.
Trial summary
The goal of this clinical trial is to assess how many patients with initially inoperable colorectal liver metastasis are able to have a liver surgery after treatment with hepatic artery infusion chemotherapy and standard of care systemic chemotherapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer, Liver Metastases From Colorectal Cancer
- What is being tested?
- Floxuridine (FUDR)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteCanada
- Study dates
- Jul 2014to Dec 2036
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Patients with resectable or ablatable lung metastasis are eligible.
- Physically able to tolerate major partial hepatectomy.
- The primary tumor may be in place at the time of registration if not obstructing the intestinal lumen or significantly bleeding. If present, the primary tumor will be resected at the time of pump placement.
- Chest, Abdominal and Pelvic CT scan with CT angiogram within 6 weeks prior to registration. (MRI angiogram with contrast of the abdomen may be substituted for CT of the abdomen).
- The patient must have inoperable liver metastases as agreed upon by any two hepatobiliary surgeons and the assigned radiologist. In the event that two hepatobiliary surgeons cannot agree, a third surgeon will be consulted. Continued discrepancy will result in the patient's case being presented at weekly hepatobiliary conference for consensus opinion. Inoperable metastases are defined as: requiring a resection that leaves less than 2 hepatic segments (not including the caudate lobe) behind with adequate arterial/portal inflow, venous outflow and biliary drainage. * A patient is considered resectable if the procedure includes a minor wedge or thermo-ablation encompassing 10% or less of the volume of the remaining 2 segments.
- Patient's liver metastases must comprise <70% of the liver parenchyma.
Show all 14Show fewer
- Female patients of child-bearing age must undergo a pregnancy test and have a negative result.
- A patient must have had prior chemotherapy.
- ECOG PS < 2.
- Within 14 days of registration: o WBC >3X10E9/L; ANC ≥ 1.5X10E9/L; Platelet count >100X10E9/L; INR < 1.5; HGB ≥ 90 g/L; Estimated creatinine clearance ≥30 ml/min (using Cockcroft and Gault formula); Total serum bilirubin <25.6 umol/L.
- Age ≥ 18 years.
- Signed informed consent.
- Subject's willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- Patients with limited/responding lung metastases on Physician's discretion.
Who cannot join
- Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration).
- Patient may not have received prior treatment with FUDR.
- Active infection, ascites, hepatic encephalopathy.
- Active concurrent malignancies, except a patient's potentially resectable colorectal primary.
- Extrahepatic metastases except for resectable or ablatable lung metastasis.
- Patient must not have obstruction of GI or GU tract.
Show all 13Show fewer
- Female patients who are pregnant or lactating.
- Patients may not be receiving any other investigational agents.
- Patients with history of primary CNS tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded (history of stroke or transient ischemic attack within 6 months prior to Day 1).
- Serious or non-healing active wound, ulcer, or bone fracture.
- Chronic daily treatment with aspirin (> 325 mg/d) or nonsteroidal anti- inflammatory medications known to inhibit the platelet function.
- Presence of bleeding diathesis or coagulopathy.
- History of serious systemic disease, including myocardial infarction within the last 6 months, uncontrolled hypertension (blood pressure of > 150/100 mmHg on medication), unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e. atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), or peripheral vascular disease (Grade II or greater).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N3M5
Rachel Roke, BSc (Hons.), MSc, 416-480-6100 ext. 685391, rachel.roke@sunnybrook.ca
Paul Karanicolas, MD, PhD
About this study
Official title: A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Best Systemic Chemotherapy in Patients With Inoperable Hepatic Metastasis From Colorectal Cancer
The goal of this clinical trial is to assess how many patients with initially inoperable colorectal liver metastasis are able to have a liver surgery after treatment with hepatic artery infusion chemotherapy and standard of care systemic chemotherapy.
- Conditions
- Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer, Liver Metastases From Colorectal Cancer, Liver Metastases of Colorectal Cancer
- Being tested
- Floxuridine (FUDR)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Floxuridine (FUDR)Drug
Floxuridine will be administered at a recommended dose of 0.12 mg/kg/day and adjusted as per participants weight and lab results.
| Study group | Role | What they receive |
|---|---|---|
| Hepatic arterial infusion pump therapy | Experimental | Hepatic arterial infusion pump therapy with floxuridine (FUDR) and dexamethasone will be administered on Day 1 of each cycle. The pump will be emptied and filled with normal saline on Day 15. Standard of care systemic chemotherapy will be administered on Day 1 and Day 15 as per the treating medical oncologist. Receives: Drug: Floxuridine (FUDR) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of participants that undergo liver resection following treatment with FUDR
To assess the rate of conversion to liver resection in patients with initially inoperable hepatic-metastases due to colorectal cancer after treatment with hepatic artery infusion pump therapy and standard of care systemic therapy.
Measured: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Secondary outcomes (6)
Time to disease progression in all participants
To evaluate time to progression (TTP).
Measured: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Time prior to disease progression in all participants
To evaluate disease-free survival (DFS).
Measured: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Time to intrahepatic disease progression in all participants
To evaluate time to disease progression in liver.
Measured: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Time to death in all participants
Overall survival
Measured: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Number of participants with complete response, partial response, progressive disease, or stable disease as per RECIST Version 1.1
To determine the response rate to systemic chemotherapy and FUDR.
Measured: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Number of participants with grade 3 or higher adverse events as per CTCAE Version 4.03
To evaluate the safety and tolerability of hepatic arterial infusion pump therapy and standard of care systemic therapy.
Measured: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2026
- Study startJul 2014
- Primary completionDec 2036 (estimated)
- Study completionDec 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal Adenocarcinoma Metastatic in the LiverStudies of the same condition, open and under way.
- More trials run by Sunnybrook Health Sciences CentreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07764497
- Sponsor's protocol ID
- HAIP-6192
- Acronym
- HAIP-6192
- Status last verified
- Jun 2026
- First submitted
- 23 Jun 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided: To be determined on a case by case basis and appropriate participant consent, research ethics board review, and execution of legal agreements.
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Best Systemic Chemotherapy in Patients With Inoperable Hepatic Metastasis From Colorectal Cancer
- ClinicalTrials.gov ID
- NCT07764497
- Acronym / sponsor ID
- HAIP-6192 / HAIP-6192
- Conditions
- Colorectal Adenocarcinoma Metastatic in the Liver, Liver Metastasis Colon Cancer, Liver Metastases From Colorectal Cancer, Liver Metastases of Colorectal Cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Sunnybrook Health Sciences CentreUniversity, hospital or other
- Study start
- Jul 2014 (actual)
- Primary completion
- Dec 2036 (estimated)
- Study completion
- Dec 2036 (estimated)
- First posted
- 14 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to assess how many patients with initially inoperable colorectal liver metastasis are able to have a liver surgery after treatment with hepatic artery infusion chemotherapy and standard of care systemic chemotherapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hepatic arterial infusion pump therapy | Experimental | Drug: Floxuridine (FUDR)Hepatic arterial infusion pump therapy with floxuridine (FUDR) and dexamethasone will be administered on Day 1 of each cycle. The pump will be emptied and filled with normal saline on Day 15. Standard of care systemic chemotherapy will be administered on Day 1 and Day 15 as per the treating medical oncologist. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Patients with resectable or ablatable lung metastasis are eligible.
- Physically able to tolerate major partial hepatectomy.
- The primary tumor may be in place at the time of registration if not obstructing the intestinal lumen or significantly bleeding. If present, the primary tumor will be resected at the time of pump placement.
- Chest, Abdominal and Pelvic CT scan with CT angiogram within 6 weeks prior to registration. (MRI angiogram with contrast of the abdomen may be substituted for CT of the abdomen).
- The patient must have inoperable liver metastases as agreed upon by any two hepatobiliary surgeons and the assigned radiologist. In the event that two hepatobiliary surgeons cannot agree, a third surgeon will be consulted. Continued discrepancy will result in the patient's case being presented at weekly hepatobiliary conference for consensus opinion. Inoperable metastases are defined as: requiring a resection that leaves less than 2 hepatic segments (not including the caudate lobe) behind with adequate arterial/portal inflow, venous outflow and biliary drainage. * A patient is considered resectable if the procedure includes a minor wedge or thermo-ablation encompassing 10% or less of the volume of the remaining 2 segments.
Key exclusion criteria (13 listed)
- Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration).
- Patient may not have received prior treatment with FUDR.
- Active infection, ascites, hepatic encephalopathy.
- Active concurrent malignancies, except a patient's potentially resectable colorectal primary.
- Extrahepatic metastases except for resectable or ablatable lung metastasis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Floxuridine (FUDR)Floxuridine will be administered at a recommended dose of 0.12 mg/kg/day and adjusted as per participants weight and lab results. | Drug | Hepatic arterial infusion pump therapy |
Primary outcome
Proportion of participants that undergo liver resection following treatment with FUDR
Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
To assess the rate of conversion to liver resection in patients with initially inoperable hepatic-metastases due to colorectal cancer after treatment with hepatic artery infusion pump therapy and standard of care systemic therapy.
6 secondary outcomes
Time to disease progression in all participants
Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Time prior to disease progression in all participants
Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Time to intrahepatic disease progression in all participants
Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Time to death in all participants
Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Number of participants with complete response, partial response, progressive disease, or stable disease as per RECIST Version 1.1
Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.
Number of participants with grade 3 or higher adverse events as per CTCAE Version 4.03
Time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: Undecided. To be determined on a case by case basis and appropriate participant consent, research ethics board review, and execution of legal agreements.
Related trials for Colorectal Adenocarcinoma Metastatic in the Liver
RecruitingPhase 1/2
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
RecruitingPhase 2
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
RecruitingPhase 2
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
Colorectal Adenocarcinoma Metastatic in the Liver
RecruitingPhase 2
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Floxuridine (FUDR) in people with Colorectal Adenocarcinoma Metastatic in the Liver and Liver Metastasis Colon Cancer, run by Sunnybrook Health Sciences Centre at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of participants that undergo liver resection following treatment with FUDR (time frame: From time of consent to approximately 42 days from last treatment with hepatic artery infusion pump therapy.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.